Business Context and Reporting Period
This Form 8-K filing by Mangoceuticals, Inc. (MGRX) is dated October 30, 2024, with the report signed on October 31, 2024. The filing addresses the company's status regarding its listing on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and listing compliance events.
Material Changes
- Reverse Stock Split: Effective October 16, 2024, the company executed a 1-for-15 reverse stock split of its outstanding common stock to address low share price concerns.
- Regaining Compliance: On October 30, 2024, Nasdaq notified the company that it regained full compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- Compliance Criteria Met: Compliance was achieved because the closing bid price of the common stock remained at or above $1.00 per share for 10 consecutive business days.
Outlook, Risks, and Management Commentary
The filing confirms that the matter regarding the minimum bid price requirement is now closed. The company had previously received a grace period ending April 29, 2024, and was granted an additional 180-day extension until October 30, 2024, to regain compliance. No forward-looking guidance, risk factors, or unusual items are disclosed in this specific report beyond the resolution of the listing deficiency.
Investor Verification Checklist
- Verify the post-split share price stability to ensure continued compliance with the $1.00 minimum bid price.
- Confirm the adjusted share count and par value following the 1-for-15 reverse stock split.
- Review the press release (Exhibit 99.1) for any additional operational updates not detailed in the 8-K text.
- Monitor future filings for any new Nasdaq deficiency notices or financial performance updates.